BioAtla, Inc. filings document the regulatory record for a clinical-stage biotechnology company developing CAB antibody therapeutics for solid tumors. Recent Form 8-K disclosures cover financial results, investor presentation materials, cost-reduction actions, executive retention compensation, financing arrangements, license-related updates and risk-linked operating disclosures.
The filings also record capital-structure and governance matters, including shareholder votes on stock issuance and reverse split authority, Series A Junior Preferred Stock issuance and elimination, Nasdaq continued-listing proceedings, and a Delaware certificate of merger connected to a common-stock reclassification.
BioAtla, Inc. (BCAB) disclosed that Dr. Eric Sievers resigned as chief medical officer on September 25, 2026, and will consult through June 30, 2027. For requested consulting services through December 31, 2026, he is eligible for a one-time $159,000 payment contingent on the company achieving certain capital-raising milestones by that date. Services from January 1 through June 30, 2027, are paid hourly at a rate proportional to his base salary at separation.
On September 24, 2026, the board reinstated selected retention-bonus terms for CEO Jay M. Short and CFO Christian Vasquez, subject to milestones by December 31, 2026. Short's $440,892 target requires 100% achievement; Vasquez's $148,888 target pays proportionally from 80% to 120% for results within 20% below or above the milestone, with no payout if it is missed by more than 20%. Both must be employed and in good standing at payout. Separate performance bonuses of $220,000 for Short and $75,000 for Vasquez depend on milestones by March 31, 2027; payment is due by April 30, 2027, subject to the same employment condition.
BioAtla, Inc. (BCAB) reported that Chief Medical Officer Eric Sievers had 134 shares of common stock withheld on August 31, 2026 to satisfy income tax and withholding obligations related to the vesting and net settlement of previously reported restricted stock units. This was not an open-market sale, and he beneficially holds 11,346 shares directly after the transaction. No transactions were made under a Rule 10b5-1 trading plan.
BioAtla, Inc. (BCAB) reported that Chief Executive Officer and director Jay M. Short, Ph.D., had 259 shares of common stock withheld on August 31, 2026 to pay income tax and related withholding obligations arising from the vesting and net settlement of previously reported restricted stock units. The company states this is not a sale of shares by Dr. Short. After this tax-withholding disposition, he holds 52,035 common shares directly and additional indirect holdings through his spouse, several 2020 irrevocable gift trusts, Capia IP, LLC, and Himalaya Parent LLC, with beneficial ownership of the latter disclaimed except to the extent of his or his spouse’s pecuniary interest. No Rule 10b5-1 trading plan is reported.
BioAtla, Inc. (BCAB) reported that Chief Financial Officer Christian Vasquez had 71 shares of common stock withheld on August 31, 2026 to pay income tax obligations related to the vesting and net settlement of previously reported restricted stock units. This was not an open-market sale; the shares were withheld by the company for tax and remittance purposes. Following this tax-withholding transaction, Vasquez directly holds 10,476 shares of BioAtla common stock, including shares purchased under the company’s ESPP.
BioAtla, Inc. (BCAB) reports that the Nasdaq Listing and Hearing Review Council has affirmed an earlier Nasdaq Hearings Panel decision to delist the company’s common stock. The action is based on prior non-compliance with Nasdaq’s $1.00 bid price requirement and the $2.5 million stockholders’ equity standard, despite a prior period of compliance with the alternative $35 million market value of listed securities standard. Unless the Nasdaq Board calls the matter for review, trading on Nasdaq is expected to be suspended at the opening of business on August 31, 2026, followed by the filing of a Form 25-NSE to remove the listing and registration. BioAtla expects its shares to be immediately eligible for quotation on the OTC Markets system under the symbol BCAB, and discloses that this change may materially adversely affect trading price and volume and make it harder for stockholders to buy or sell shares. The company’s strategic review process, initiated in March 2026 to explore options to maximize shareholder value, remains ongoing.
BioAtla, Inc. is a clinical-stage oncology company focused on conditionally active biologics. For the quarter ended June 30, 2026, it reported $6.5 million of collaboration revenue, entirely from amending its license with Context Therapeutics, and net income of $0.5 million, versus a $18.7 million loss a year earlier. Operating expenses fell sharply as Phase 2 trials concluded and a major restructuring was implemented.
Despite the profitable quarter, BioAtla recorded a $5.9 million loss for the first half of 2026, an accumulated deficit of $551.5 million, and cash and cash equivalents of just $1.5 million. Management disclosed substantial doubt about its ability to continue as a going concern. The company is pursuing strategic alternatives, has reduced its workforce by about 70%, paused new enrollment in its BA3182 Phase 1 trial, and is reassessing timelines for a potential Phase 3 study of BA3021. Liquidity actions include converting a $7.5 million pre-paid advance into equity and limited use of a $15 million standby equity purchase agreement.
BioAtla, Inc. held its 2026 annual meeting of stockholders on July 16, 2026, with 906,983 shares of common stock represented in person virtually or by proxy, approximately 55% of the total outstanding shares eligible to be voted. Stockholders considered director elections, auditor ratification and executive compensation.
Two Class III directors, Jay M. Short, Ph.D. and Edward Williams, were elected to three-year terms. Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. A non-binding advisory resolution approving the compensation of named executive officers also received stockholder approval.
BioAtla, Inc. Chief Financial Officer Christian Vasquez reported routine tax-withholding transactions related to equity compensation, not open‑market trades. On two dates in 2026, a total of 257 shares of common stock were withheld by the company to cover income tax obligations from vesting restricted stock units.
After the most recent withholding of 82 shares at $3.93 per share, Vasquez directly owned 10,347 shares of common stock. The reported share amounts have been adjusted to reflect a 50‑for‑1 share consolidation effective on April 6, 2026.
BioAtla, Inc. director and Chief Executive Officer Jay M. Short reported routine tax-related share dispositions rather than open-market sales. On March 12, 2026 and May 31, 2026, a total of 898 shares of common stock were withheld by the company to cover income tax obligations tied to vesting restricted stock units.
After the most recent withholding of 259 shares at $3.93 per share, Short directly holds 52,294 common shares, with additional indirect holdings through entities and a spouse. Reported amounts reflect a 50-for-1 share consolidation of BioAtla common stock effective on April 6, 2026.
BioAtla, Inc. Chief Medical Officer Eric Sievers reported routine tax-related share withholdings, not open-market sales. On two dates, a total of 494 common shares were withheld by the company to satisfy income tax obligations tied to vested restricted stock units. Following the most recent withholding, Sievers directly owned 11,840 common shares. The reported amounts have been adjusted to reflect a 50-for-1 share consolidation effective on April 6, 2026.